Trident Medical Center | |
9330 Medical Plaza Dr, Charleston, South Carolina 29406 | |
(843) 847-4100 | |
Name | Trident Medical Center |
---|---|
Type | Acute Care Hospital |
Location | 9330 Medical Plaza Dr, Charleston, South Carolina |
Ownership | Proprietary |
Emergency Services | Yes |
Medicare ID (CCN) | 420079 |
NPI Number | 1366496937 |
Organization Name | TRIDENT MEDICAL CENTER LLC |
Doing Business As | TRIDENT MEDICAL CENTER |
Address | 9330 Medical Plaza Dr, Charleston, SC 29406 |
Hospital Type | General Acute Care Hospital |
Phone Number | 843-847-7000 |
News Archive
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Scientists from The University of Texas at Arlington and the University of North Texas Health Science Center are building a prototype for an implantable in-line shunt flow monitoring system that would deliver both on-demand and continuous readings of hydrocephalus.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
Workers experiencing job and financial insecurity are less likely to follow the CDC's guidelines for COVID-19, such as physical distancing, limiting trips from home and washing hands, according to a Washington State University study.
› Verified 8 days ago
NPI Number | 1386721405 |
Organization Name | TRIDENT MEDICAL CENTER, LLC |
Doing Business As | TRIDENT MEDICAL CENTER |
Address | 9330 Medical Plaza Dr, Charleston, SC 29406 |
Hospital Type | General Acute Care Hospital |
Phone Number | 843-797-7000 |
News Archive
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Scientists from The University of Texas at Arlington and the University of North Texas Health Science Center are building a prototype for an implantable in-line shunt flow monitoring system that would deliver both on-demand and continuous readings of hydrocephalus.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
Workers experiencing job and financial insecurity are less likely to follow the CDC's guidelines for COVID-19, such as physical distancing, limiting trips from home and washing hands, according to a Washington State University study.
› Verified 8 days ago
NPI Number | 1649478850 |
Organization Name | TRIDENT MEDICAL CENTER LLC |
Address | 9298 Medical Plaza Dr, Charleston, SC 29406 |
Hospital Type | General Acute Care Hospital |
Phone Number | 843-876-7080 |
News Archive
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Scientists from The University of Texas at Arlington and the University of North Texas Health Science Center are building a prototype for an implantable in-line shunt flow monitoring system that would deliver both on-demand and continuous readings of hydrocephalus.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
Workers experiencing job and financial insecurity are less likely to follow the CDC's guidelines for COVID-19, such as physical distancing, limiting trips from home and washing hands, according to a Washington State University study.
› Verified 8 days ago
NPI Number | 1659579084 |
Organization Name | TRIDENT MEDICAL CENTER, LLC |
Address | 9330 Medical Plaza Dr, Charleston, SC 29406 |
Hospital Type | General Acute Care Hospital |
Phone Number | 843-847-4140 |
News Archive
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Scientists from The University of Texas at Arlington and the University of North Texas Health Science Center are building a prototype for an implantable in-line shunt flow monitoring system that would deliver both on-demand and continuous readings of hydrocephalus.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
Workers experiencing job and financial insecurity are less likely to follow the CDC's guidelines for COVID-19, such as physical distancing, limiting trips from home and washing hands, according to a Washington State University study.
› Verified 8 days ago
NPI Number | 1720169071 |
Organization Name | UNIVERSITY FAMILY MEDICINE |
Address | 9298 Medical Plaza Dr, Charleston, SC 29406 |
Hospital Type | General Acute Care Hospital |
Phone Number | 843-797-7000 |
News Archive
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Scientists from The University of Texas at Arlington and the University of North Texas Health Science Center are building a prototype for an implantable in-line shunt flow monitoring system that would deliver both on-demand and continuous readings of hydrocephalus.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
Workers experiencing job and financial insecurity are less likely to follow the CDC's guidelines for COVID-19, such as physical distancing, limiting trips from home and washing hands, according to a Washington State University study.
› Verified 8 days ago
NPI Number | 1861447773 |
Organization Name | TRIDENT MEDICAL CENTER, LLC |
Doing Business As | TRIDENT MEDICAL CENTER |
Address | 9330 Medical Plaza Dr, Charleston, SC 29406 |
Hospital Type | General Acute Care Hospital |
Phone Number | 843-847-7000 |
News Archive
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Scientists from The University of Texas at Arlington and the University of North Texas Health Science Center are building a prototype for an implantable in-line shunt flow monitoring system that would deliver both on-demand and continuous readings of hydrocephalus.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
Workers experiencing job and financial insecurity are less likely to follow the CDC's guidelines for COVID-19, such as physical distancing, limiting trips from home and washing hands, according to a Washington State University study.
› Verified 8 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Scientists from The University of Texas at Arlington and the University of North Texas Health Science Center are building a prototype for an implantable in-line shunt flow monitoring system that would deliver both on-demand and continuous readings of hydrocephalus.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
Workers experiencing job and financial insecurity are less likely to follow the CDC's guidelines for COVID-19, such as physical distancing, limiting trips from home and washing hands, according to a Washington State University study.
› Verified 8 days ago
Musc Medical Center Acute Care Hospital Location: 169 Ashley Ave, Charleston, South Carolina 29425 Phone: (843) 792-2300 | |
Bon Secours-st Francis Xavier Hospital Acute Care Hospital Location: 2095 Henry Tecklenburg Drive, Charleston, South Carolina 29414 Phone: (843) 402-1006 | |
Trident Medical Center Acute Care Hospital Location: 9330 Medical Plaza Dr, Charleston, South Carolina 29406 Phone: (843) 847-4100 | |
Roper Hospital Acute Care Hospital Location: 316 Calhoun St, Charleston, South Carolina 29401 Phone: (843) 724-2800 | |
Palmetto Lowcountry Behavioral Health Psychiatric Hospital Location: 2777 Speissegger Drive, Charleston, South Carolina 29405 Phone: (843) 747-5830 |